F
Fred Thomas Bizzarro
Researcher at Hoffmann-La Roche
Publications - 14
Citations - 915
Fred Thomas Bizzarro is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Glucokinase & Tocotrienol. The author has an hindex of 9, co-authored 14 publications receiving 870 citations. Previous affiliations of Fred Thomas Bizzarro include University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy
Joseph Grimsby,Ramakanth Sarabu,Wendy Lea Corbett,Nancy-Ellen Haynes,Fred Thomas Bizzarro,John W. Coffey,Kevin Richard Guertin,Darryl W. Hilliard,Robert Francis Kester,Paige Erin Mahaney,Linda Marcus,Lida Qi,Cheryl Spence,John Tengi,Mark A. Magnuson,Chang An Chu,Mark T. Dvorozniak,Franz M. Matschinsky,Joseph F. Grippo +18 more
TL;DR: In several rodent models of type 2 diabetes mellitus, GKAs lowered blood glucose levels, improved the results of glucose tolerance tests, and increased hepatic glucose uptake, which may lead to the development of new drug therapies for diabetes.
Journal ArticleDOI
Syntheses of (2R, 4′R, 8′R)‐α‐Tocopherol and (2R, 3′E, 7′E)‐α‐Tocotrienol
TL;DR: In this paper, a reaction sequence of trimethyl-hydroquinone with methyl vinyl ketone in acidic methanol gave rac.-2methoxy-2,5,7,8,8-tetramethyl-chroman-6-ol (8), which was converted to (2R, 4′R, 8′R)-α-tocopherol (1d) using a side chain derived from phytol.
Journal ArticleDOI
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
Ramakanth Sarabu,Fred Thomas Bizzarro,Wendy Lea Corbett,Mark T. Dvorozniak,Wanping Geng,Joseph F. Grippo,Nancy-Ellen Haynes,Stanley D. Hutchings,Lisa M. Garofalo,Kevin Richard Guertin,Darryl W. Hilliard,Marek M. Kabat,Robert Francis Kester,Wang Ka,Zhenmin Liang,Paige Erin Mahaney,Linda Marcus,Franz M. Matschinsky,David J Moore,Jagdish Kumar Racha,Roumen Nikolaev Radinov,Yi Ren,Lida Qi,Michael Pignatello,Cheryl Spence,Thomas G. Steele,John Tengi,Joseph Grimsby +27 more
TL;DR: Piragliatin was found to lower pre- and postprandial glucose levels, improve the insulin secretory profile, increase β-cell sensitivity to glucose, and decrease hepatic glucose output in patients with T2D.
Patent
Heteroaromatic glucokinase activators
Fred Thomas Bizzarro,Wendy Lea Corbett,Joseph F. Grippo,Nancy-Ellen Haynes,George W. Holland,Robert Francis Kester,Paige Erin Mahaney,Ramakanth Sarabu +7 more
TL;DR: In this paper, a 2,3-Di-substituted N-hetero-aromatic propionamides with substitution at the 3 position being a substituted phenyl group and at the 2position being a methyl cycloalkyl ring were used to increase insulin secretion in the treatment of type II diabetes.
Patent
Para-amine substituted phenylamide glucokinase activators
TL;DR: Para-alkyl, aryl, cycloheteroalkyl or heteroaryl [carbonyl or sulfonyl] amino substituted phenyl amides active as glucokinase activators to increase insulin secretion which makes them useful for treating type II diabetes.